Xinqing (2016) Comparing national home-keeping and the regulation of translational stem cell applications: an international perspective. Social Science and Medicine, 153. pp. 240-249.
Research into the regulation of stem cell science and semi-structured interviews have been held in the following countries: China, Japan, Thailand, South Korea, Vietnam, Taiwan, Europe, Malaysia and India. Archival research was done on the regulation in the USA. former is depicted as ethical, sophisticated, scientifically advanced; the latter as unethical, profit-motivated and uninterested in scientific advance (Sipp, 2012; McMahon & Thorsteinsdóttir, 2010) . But by defining the difference in moral terms, critics do not do justice to the efforts of many researchers involved in stem cell therapy research and provision, for example, in Asia. In fact, we can discern only a few players that can afford to conduct clinical trials in tightly regulated research fields in ways that match the ideals of the dominant international science community, and only a few corrupt so-called 'snake-oil providers' (Sleeboom-Faulkner, 2014) .
Instead, a very large grey area of stem cell-related activities exists in which stem cell scientists, doctors, politicians and regulators accommodate, adjust, circumvent and alter regulatory spaces to help advance clinical research in ways that suits their circumstances.
The current use of the binary between bona fide science and snake oil traders has its roots in a situation in which a few international organisations and countries driven by members from well-funded, cautious research laboratories set the M A N U S C R I P T
A C C E P T E D ACCEPTED MANUSCRIPT 3 standards. Those that do not stick to agreed conventions are seen as undisciplined and fraudulent (Sipp, 2012; Bharadwaj & Glasner, 2008) . This binary has led to the tainting of a large group of under-resourced researchers, and to one-sided portrayals of their aims. Scientists delineate themselves from the 'science' of other scientists, claiming scientific integrity for themselves. Although this 'boundary work' is inherent to the scientific community (Gieryn, 1983; Gilbert & Mulkay, 1984; Salter & Qiu 2009) , it is now played out on a global level, expressed in papers on 'research ethics' and 'good practice' at international scientific conferences.
Recent years have seen a new regime of coordination of medical practices linking medicine and biology together that has led to the increased articulation of genomic biology, multicentre clinical trials, organised patient communities, and biobanks, which depend on sophisticated laboratories, reliable instruments and devices that produce exchangeable results. Standard setting, guidelines and regulation are central to this regime. Thus 'regulatory objectivity' (Cambrosio, Keating, Schlich an&d Weisz, 2006) defines the contents of what the dominant science community regard as correct practices (Birch, 2012) . These standards are often conventions: what counts here is that results are compatible with other laboratories, whereby 'truth' and 'accuracy' become dependent on these conventions. In regenerative medicine (RM), referring to research and therapies using the regenerative powers of the body, the International Stem Cell Initiative (ISCI), for example, has taken the initiative to define pluripotency and assays, and the media and reagents used to produce them (Eriksson & Webster, 2008) . Standards do not only facilitate exchange, they can also define the clinical criteria in terms of diagnosis. Thus, scientific standards and assays for mesenchymal stem cells are critical both to the advancement of scientific development and clinical practice (Bianco, Cao, Frenette, Mao, Robet, Simmons, et 4 al., 2013) . Crucially, the exchangeability and common use of data require the deployment of similar equipment, devices and assays. This has major economic and intellectual property rights (IPR) implications to the advantage of those that set the standards, and to the disadvantage of the reputation of researchers that cannot comply with them (PRNewswire, 2014; Birch 2012).
These developments pressurise scientists all over the world to follow the standards of elite laboratories. At the elite levels, scientific knowledge is sanctioned by international peer-reviewed journals, regulation vetted by expert committees in modern bureaucracies, and novelty defined by IPR. Here, political discourses on norms and values define the ethics acceptable to a small number of societies (Timmermans & Epstein, 2010; Birch, 2012) . International collaboration, then, requires elite laboratories in most countries, including those with few resources, to demand regulations that enforce 'global' standards. But the necessity to purchase costly equipment and resources has also led to resistance against regulatory norms and standards by those less well endowed (Sleeboom-Faulkner, 2013 
investigational studies or clinical trials; the quality of preclinical studies and toxicity studies; the fees charged for investigational studies using unauthorised stem cell products; and the ways of marketing therapy products. Global variability of therapy marketing and patient demand complicates the picture of compliance and resistance even further (Petryna, 2009; Chen & Gottweis, 2011) . This variability has resulted in a situation in which the relationship between patients and doctors is conditioned by availability of research funding, expertise and medical facilities, as well as collaborative networks and regulatory constraints.
National home-keeping
At the intersection of the international and local governance of stem cell science, we locate a form of decision-making, which we refer to as 'national home-keeping'.
National home-keeping is a heuristic notion we use to capture policies designed when countries face universal standards, often created 'elsewhere', that are not conducive to local policies of economic, health and scientific development. In this article, we illustrate how policies of national home-keeping condition stem cell innovation through regulation and regulatory instruments.
This article follows global assemblage approaches (Ong & Collier, 2005;  Sleeboom-Faulkner, 2014) that avoid assuming an encompassing global force or a pre-existing local path, but investigate the dynamic interactions among international, regional, and local politics. Although various works in particular on human embryonic stem cell research have appeared in a global setting (Thompson, 2013; Gottweis, Salter & Waldby, 2009; Webster, 2013; Zhang, 2012; Bharadwaj & Glassner, 2008; Sleeboom-Faulkner, 2014) , issues discussed in these works regard the status of the embryo and gamete donation rather than issues of clinical M A N U S C R I P T
A C C E P T E D ACCEPTED MANUSCRIPT 6 applications. 1 Nevertheless, several of these works have emphasised the importance of analysing RM in the context of globalisation, global politics and global governance (Thompson, 2013; Gottweis, Salter & Waldby, 2009 ). These and other works (Salter & Qiu, 2009; Salter, Zhou & Datta, 2015; Thompson, 2013; Bharadwaj and Glasner, 2008) which we correlate with policies aimed to enable local development of the field. We discuss examples of locally mobilised tools in Part II, with the exception of 'implementation'. We analyse 'implementation' in Part III together with the pattern we delineated in home-keeping policies of the countries examined. This pattern is based on the kind of regulatory policies over six years (2008) (2009) (2010) (2011) (2012) (2013) (2014) : adjustment, radical change, impasse and early formulation of regulation (see Table 1 ). The identification of this pattern, in turn, led us to analyse the similarities and difference 
II. National home-keeping and regulatory policy-making
National home-keeping policies direct the development of science to articulate international regulatory trends with socio-political and economic policies and home conditions. Developments in cell therapies are subject to changes in science policies, science funding and science regulation The effectiveness and reach of science regulation, however, can be steered in many ways, for example, by assigning a particular level of authority to regulation, through funding-linked incentives, such as research review, scientific protocols and research ethics, and through permissions, such as for investigational studies/trials, experimental research spaces for research involving human subjects and marketing licenses. In this section, we discuss how innovation for stem cell therapies in particular is conditioned through regulation in Asia and in EU and the USA. Apart from in the first subsection, we focus on the EU and USA to indicate the variability in regulatory provisions in the part of the world often associated with advanced science and technology. It also serves as a reference in discussing national home-keeping in Asia in Part III. The section sketches the variety and flexibilities of the regulatory landscape in terms of authority, permission, space and acceleration, embodied in policies of 'national home-keeping'.
Regulatory authority
National home-keeping policies can condition regulatory tools. Thus, countries might diversely regulate the development of stem cell applications by legal means (hard law), formally sanctioning violation, or through guidelines, that is, soft law. Some countries, such as Japan, until recently, have predominantly used soft law, which can be very effective when social/institutional controls are available at the ground level Ida, 2002) . 1 Other countries make use of a range of regulatory levels with varying degrees of authority. For instance, China has laws (法), administrative regulations (行 政法规), departmental regulation (部门规章), ethical principles (伦理原则) and administrative measures (管理办法) (also see Wahlberg et al., 2013) . New regulation usually comes out as draft (草案) or trial regulation (試行), amenable to change. In addition police and armed forces have their own regulation for scientific research and medical treatment in hospitals and research centres.
In Europe and the USA we see major differences in the organisation of regulations and the status assigned to different forms, with traditionally a relatively high reliance on soft law in Anglo-American countries compared to continental Europe. For example, the UK is well known to have a highly regulated system but liberal laws for stem cell research, while France is the opposite. Furthermore, national authorities implement the European Medicines Agency (EMA) regulations through varying national regulatory and/or legal mechanisms. In the USA, the Food and Drug Administration (FDA) regulates translational stem cell research federally, but leaves powers to the private sector and state governments. Finally, the status and authority of regulatory organs are subject to constant innovation, as will become clear below. The political and legal status of regulation is crucial in understanding its impact.
Permissions for investigational studies -geographic dimensions
Innovative stem cell treatment in most countries requires permission from a local institutional review board (IRB) or equivalent and from a higher-tier organisation at In some countries, national permission for the clinical application of stem cell products may only be necessary for marketization. This means that hospitals can provide treatment using unauthorised stem cell products as long as they do not charge for the stem cell products; they charge for the 'service'. Alternatively, stem cell products are applied off-label for indications without evidence for their safety and efficacy. Such methods enable clinics in the USA, China and India to continue to provide treatments that have not been recognised at home (Richer, 2011) . In the USA permission can be acquired to take an experimental drug across state boundaries.
Thus, through the Investigational New Drug (IND) programme in the USA, a pharmaceutical company can obtain FDA permission to ship an experimental drug across states (usually to clinical investigators) before an application for marketing a drug has been approved (US FDA, 2014a). This possibility opens up a large pool of potential subjects for clinical trials.
Creating spaces for procurement of innovative treatment and experimentation (Lowdell, Birchall, & Thrasher, 2012; Mahalatchimy et al, 2012) . It can be scaled up and used across Europe, with the manufacturer paying for the process rather than the product (MHRA, 2007; European Commission, 2014) .
Applications can receive extra incentives in terms of fees and priority at any stage of the development of therapeutic products through the Orphan Drug Designation (ODD) if certain 'rare disease' criteria are met. For instance, Multi-Stem, a US-based company, which created a graft versus host disease (GvHD) prophylaxis for leukaemia patients receiving allogeneic (from others) haemapoeitic stem cells (HSCs), has received ODD both from the FDA and EMA for its allogeneic multipotent adult progenitor cell based 'MultiStem therapy' (Athersys Inc., 2013) .
Acceleration of translational pathways
In the EU, some stem cell products may be used clinically without marketing licence.
This, however, does not mean that they are uncontrolled, as is illustrated by the ODD, whether it should be treated as a biological drug, regulated by the FDA (Cyranoski, 2013a) . Another example is the contentious interpretation of the 'non-routine' use of stem cell products for individual patients authorised through the EU Hospital Exemption (EBE, 2011). A last example from Thailand relates to the term 'stem cell therapy', whereby the notion of 'stem cell' indicates that it requires state authorisation. To avoid criticism, companies advertise the application of unauthorised stem cell products as 'cell treatment' (Chaisinthop, 2014) .
The 2013 overview of stem cell and genetic engineering products with marketing permission in Figure 1 gives a general idea of how countries make regulation work for innovation in RM. As will become clear below, this figure does not represent so much the scientific advancement or productivity in RM of a country, as it does the kind of regulatory policies it has adopted. Texas, 2013) ; Japan and India's joint-venture Niscell, which provides autologous (from self) stem cell therapy and conducts clinical stem cell trials in Malaysia (Niscell, 2013) ; and India's Stempeutics' clinical stem cell trials in Malaysia (Stempeutics, 2013; Bionexus, 2014) . Regulation of translational stem cell applications in these host countries tends to be brief and general, so that the conditions under which authorised clinical trials take place are unclear (TMC, 2009; MOH Malaysia, 2013; Thomson Reuters, 2015) . Hearticellgram and Cartistem for Osteoarthritis and Cupistem for Crohn's fistula (Wohn, 2012) , followed by many others (see figure 1 ).
M A N U S C R I P T A C C E P T E D
Having been frustrated by its slow regulatory bureaucracy, and hoping to take Therapeutic Products Act (PMD. Act), enacted on 25 November 2014, stipulates that the Pharmaceuticals and Medical Devices Agency (PMDA) and the MHLW provides an expedited approval system for regenerative medical products. After the safety is confirmed and the results predict likely efficacy, the product will be given conditional, time-limited marketing authorisation (PMDA, 2014; Azuma, 2015) . This radical regulatory reform, allowing market authorisation before the provision of scientific evidence through clinical trial (Cyranoski, 2013b; Nikkei, 2014) , has already attracted the interest of large companies, such as Athersys, Mesoblast, and Cytori Therapeutics (Market Watch, 2014) . Also, companies from elsewhere in Asia, such as India's Stempeutics, consider approaching Japanese partners (interview J, 23/09/13-India). Nevertheless, considering the fear of scandal from the side of regulators, and the uncertainties around post-marketing conditions of cell products (interview K, 1/11/13, Japan), it might take some time before new stem cell products will be given marketing permission.
In short, our examination of the ways in which countries undertake boundary-work to harness the regulation of RM in an international context led us to categorise countries according to their size, the state's ability to accumulate resources, healthcare demands, established traditions of scientific governance, and economic and scientific ambitions (see Table 2 ). 
IV. International stem cell organisations and networks
Regulatory diversity regarding translational stem cell science has led to initiatives aimed to harmonise international regulation and standards. They not only facilitate exchanges in scientific knowledge, but also funnel and discipline their membership by stipulating ethical review, scientific protocols and common scientific standards.
Examples of such organisations are the Alliance for Harmonisation of Cellular recently reported on the completion of a phase II stem cell trial for knee osteoarthritis (KOA), claimed to follow 'international' standards. 27 Since the government has prohibited treatments using unauthorised stem cell products, 'regulatory uncertainty' led CBMG to apply for marketing permission of the autologous stem cells under medical device regulation. Although this is a quick method of acquiring permission, it is limited to the hospital in which it is obtained. For this reason, a company will typically conduct multicentre trials for a disease in a group of hospitals, and if it proves safe and efficacious, receive permission to sell in these hospitals.
The exemplified organisations illustrate the existence of international organisations with contrasting aims. They look to international and local allies for support of their research methods and standards and seek shelter under the protective umbrellas of international professional communities and local business communities. But the roots and targets of these movements lie mainly in the national home-keeping policies that articulate international regulatory trends with workable rules for regulation, funding, infrastructures, and treatment on a national level.
Conclusion
As Regulatory diversity, we argued, has led to the emergence of international organisations that promote dominant forms of ethical review, scientific protocols and common scientific standards on regional and international levels. This and dissatisfaction with national home-keeping policies has also led to the formation of transnational scientific collaborations and networks that champion and practise 'alternative' therapeutic practices and evaluation methods. We argued that it is misleading to represent this friction as a binary between bona fide scientists and rogue scientists. In general, the globalisation of stem cell science has created a greater overall need to confirm compliance with globally dominant standards and regulation.
It is the diversity of ways in which countries formulate and enforce these standards through their own regulatory boundary work, which is at stake.
In contrast with studies that frame translational stem cell science in terms of bona fide and rogue practices and Western (or international) versus local, this study on national home-keeping shows that 'international regulation' can be a flag proudly http://www.nature.com/news/controversial-stem-cell-company-moves-treatmentout-of-the-united-states-1.12332 Cyranoski, D. (2013b) . Japan to offer fast-track approval path for stem cell therapies, Nature Medicine, 19 (5) 
Large country size and centralised accumulation of resources
Enable large-scale investment scientific fields, but facilitates regional diversity and hinders regulatory implementation
Established traditions of governing RM
Institutional stickiness can hinder radical change High healthcare demand High demand for treatment as push factor of scientific application RM as economic growth tool Encourages regulation that allows competitive applications Position in the international science community 
